Stĕpán J, Smíd M, Prokes M, Palicka V, Honzáková L, Havelka S, Blahos J, Bayer M
III. Interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 1998 Nov 30;137(23):707-15.
The objective of this study was to evaluate expenditures and efficacy of osteoporosis treatment in the Czech Republic (CZ) (1.38 million women and 0.99 million men > 55 years of age).
Demographic data, incidence of hip fractures and prevalence of osteoporosis and osteopenia in Czech women and men, cost burden to healthcare agencies due to hip fractures and costs of diagnostic procedures, preventive measures and therapies of osteoporosis were obtained from published data and from database of the main health insurance agency (VZP) and the State Institute for Drug Control. The direct costs for treatment of hip fractures in the CZ in 1997 averaged Kc (Czech Crown) 2.5 billion, diagnosis of osteoporosis, Kc 150 million, prevention of osteoporosis using hormone replacement therapy, Kc 66 million, and treatments of osteoporosis which has been applied to less than 5% of osteoporosis patients, 482 million. However, despite the continuously increasing expenditures for treatments of osteoporosis, the incidence of hip fractures doubled in the last 10 years. This is mainly due to increased life expectancy in Czech women and men.
The results of this first economic evaluation of diagnosis, treatment and consequences of osteoporosis in the CZ indicate a need for conceptual decisions in both treatment and prevention of osteoporosis.
本研究的目的是评估捷克共和国（CZ）（138万55岁以上女性和99万55岁以上男性）骨质疏松症治疗的支出和疗效。
捷克女性和男性的人口数据、髋部骨折发生率、骨质疏松症和骨质减少症患病率、髋部骨折给医疗机构带来的成本负担以及骨质疏松症诊断程序、预防措施和治疗的成本，均来自已发表的数据以及主要健康保险公司（VZP）和国家药物控制研究所的数据库。1997年，捷克治疗髋部骨折的直接成本平均为25亿捷克克朗（Kc），骨质疏松症诊断成本为1.5亿捷克克朗，使用激素替代疗法预防骨质疏松症的成本为6600万捷克克朗，而应用于不到5%骨质疏松症患者的骨质疏松症治疗成本为4.82亿捷克克朗。然而，尽管骨质疏松症治疗支出持续增加，但在过去10年中，髋部骨折的发生率翻了一番。这主要是由于捷克女性和男性的预期寿命增加。
对捷克共和国骨质疏松症的诊断、治疗及后果进行的首次经济评估结果表明，在骨质疏松症的治疗和预防方面都需要做出概念性决策。
